Posted by ABMN Staff on May 6th, 2024
Biogen (NASDAQ:BIIB – Free Report) had its price target upped by HSBC from $339.00 to $342.00 in a research note published on Friday, Benzinga reports. They currently have a buy rating on the biotechnology company’s stock.
Several...
More of this article »